The A-share diet pill concept fluctuated higher. Kanghui Pharmaceutical went up and down, Kangpeng Technology rose more than 6%, and Nanowei Technology, Haoyuan Pharmaceutical, Medici, and Prius followed suit.

The A-share diet pill concept fluctuated higher. Kanghui Pharmaceutical went up and down, Kangpeng Technology rose more than 6%, and Nanowei Technology, Haoyuan Pharmaceutical, Medici, and Prius followed suit.

Zhitong FinanceApr 9 13:55

CRO concept stocks surged higher in the afternoon. Zhaoyan Pharmaceutical rose more than 8%, Tiger Pharmaceuticals rose more than 7%, and Norske, Haoyuan Pharmaceuticals, and Pharmaceutical Stone Technology rose more than 4%.

CRO concept stocks surged higher in the afternoon. Zhaoyan Pharmaceutical rose more than 8%, Tiger Pharmaceuticals rose more than 7%, and Norske, Haoyuan Pharmaceuticals, and Pharmaceutical Stone Technology rose more than 4%.

Zhitong FinanceApr 9 13:34

The concept of diet pills fluctuated and declined, with Aimeike falling more than 7%, Huadong Pharmaceutical and Zhengguang shares falling by more than 4%, and Haoyuan Pharmaceuticals, Medici, and Shengnuo Biotech.

The concept of diet pills fluctuated and declined, with Aimeike falling more than 7%, Huadong Pharmaceutical and Zhengguang shares falling by more than 4%, and Haoyuan Pharmaceuticals, Medici, and Shengnuo Biotech.

Zhitong FinanceApr 8 09:49

Haoyuan Chemexpress to Issue 822 Million Yuan Worth of Convertible Bonds

Shanghai Haoyuan Chemexpress (SHA:688131) proposed to issue convertible corporate bonds worth up to 822.4 million yuan, the company said in its filing on the Shanghai Stock Exchange. The proceeds from

MT NewswiresMar 25 16:08

Haoyuan Chemexpress to Raise Subsidiary's Capital by 200 Million Yuan

Shanghai Haoyuan Chemexpress (SHA:688131) plans to raise the capital of subsidiary Anhui Haoyuan Pharmaceutical by 200 million yuan through debt-for-equity swaps, the company said in the filing on the

MT NewswiresMar 25 16:04

Haoyuan Pharmaceutical (688131.SH): Capital increase of 200 million yuan for wholly-owned subsidiary through debt-to-equity swaps

Gelonghui, March 22丨Haoyuan Pharmaceutical (688131.SH) announced that on March 22, 2024, the company held the 34th meeting of the 3rd board of directors and the 32nd meeting of the 3rd board of supervisors to review and pass the “Proposal on Increasing the Capital of Wholly-owned Subsidiaries by using debt-for-equity swaps”, and agreed that the company would use funds raised to increase the capital of Anhui Haoyuan by RMB 20.00 million. After the capital increase was completed, the registered capital of Anhui Haoyuan increased from RMB 20 million to RMB 40 million. It is a wholly-owned subsidiary of the company.

Gelonghui FinanceMar 22 18:40